Contemporary Pharmacotherapy for OAB 2023: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2023)

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. The publication of the recently updated AUA/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Guideline titled “Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults,” the proceedings of the 7th International Consultation on Incontinence, as well as European Association of Urology Guidelines have maintained considerable interest in this area among researchers and practitioners. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of OAB, review currently available agents and discuss agents in development.


Independent educational grant support provided by:

  • Astellas
  • Urovant Sciences, Inc. 

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Define the similarities and differences between the various oral pharmacotherapies for OAB.
  2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy.
  3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
  4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
  5. Discuss potential future pharmacological pathways and therapies for OAB.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Eric Scott Rovner, MDAllerganConsultant or AdvisorCurrent
 MedtronicsConsultant or AdvisorCurrent
 UrovantScientific Study or TrialCurrent
 BluewindConsultant or AdvisorCurrent
 HologixConsultant or AdvisorCurrent
 uromedicaScientific Study or Trial04/04/2023
 ValenciaConsultant or AdvisorCurrent
 AvationConsultant or AdvisorCurrent
 Boston ScientificMeeting Participant or LecturerCurrent
 AxonicsConsultant or AdvisorCurrent
 EG-427Consultant or AdvisorCurrent
 IronwoodScientific Study or TrialCurrent
 Synapse ICConsultant or AdvisorCurrent
 ViveveConsultant or Advisor04/04/2023
 UrocureStock OptionCurrent
Alan J. Wein, MDUrovantConsultant or AdvisorCurrent
Christopher R. Chapple, MDSymimeticsConsultant or AdvisorCurrent
 Urovant SciencesConsultant or AdvisorCurrent
 AllerganMeeting Participant or LecturerCurrent
 AllerganConsultant or Advisor5/18/2021
 AstellasConsultant or Advisor5/14/2021
 AstellasMeeting Participant or Lecturer3/29/2022
 Bayer Schering Parma AGConsultant or Advisor11/12/2021
 Bayer Schering Parma AGScientific Study or Trial8/23/2021
 TakedaConsultant or Advisor6/23/2021
 B. BraunMeeting Participant or LecturerCurrent
 ProverumConsultant or AdvisorCurrent



PDF icon Education Council Disclosures_2022.pdf


PDF iconCOI Review Work Group Disclosures_2023_0.pdf


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.


Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2023
Expiration Date: May, 2024


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic



The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.